Revia

Pruritus, Caloric Restriction, Obesity + 8 more
Treatment
7 FDA approvals
7 Active Studies for Revia

What is Revia

NaltrexoneThe Generic name of this drug
Treatment SummaryNaltrexone is a drug derived from noroxymorphone and is used to block the effects of narcotics and alcohol. It is more potent and longer lasting than naloxone, which makes it a good treatment for heroin addiction. Naltrexone has been approved by the FDA to treat alcohol dependence.
Naltrexone Hydrochlorideis the brand name
image of different drug pills on a surface
Revia Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Naltrexone Hydrochloride
Naltrexone
1998
59

Approved as Treatment by the FDA

Naltrexone, otherwise known as Naltrexone Hydrochloride, is approved by the FDA for 7 uses including Opioid-Related Disorders and Opioid Dependence .
Opioid-Related Disorders
Helps manage Opioid Dependence
Opioid Dependence
Helps manage Opioid Dependence
Alcohol Dependency
Helps manage Alcohol Dependency
Therapeutic procedure
Used to treat inadequate alternative treatment options in combination with Morphine
Alcoholism
Helps manage Alcohol Dependency
Pain
Used to treat Severe Pain in combination with Morphine
Opiate Substitution Treatment
Used to treat requiring long-term opioid treatment in combination with Morphine

Effectiveness

How Revia Affects PatientsNaltrexone is a drug that blocks the effects of opioids in the body and is used to treat alcohol dependence. It stops the body from feeling the effects of opioids taken externally and blocks physical dependence on them. When taken with opioids, it can cause withdrawal symptoms in those who are physically dependent on them.
How Revia works in the bodyNaltrexone is a drug that blocks the effects of opioids in the brain. It does this by attaching itself to opioid receptors, which prevents other molecules, like endorphins, from binding to them. This stops the effects opioids have on the body, like pain relief, miosis, and respiratory depression. The major metabolite of naltrexone, 6-β-naltrexol, also has opioid blocking activity. It is unclear how it works to help treat alcoholism.

When to interrupt dosage

The serving of Revia is contingent upon the diagnosed problem, including Opioid Dependence, a reduced-calorie diet, and BMI >27 kg/m2. The measure of dosage diverges as per the method of delivery shown in the accompanying table.
Condition
Dosage
Administration
Opioid-Related Disorders
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular
Comorbidity
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular
Chronic Weight Management therapy
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular
Caloric Restriction
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular
Pruritus
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular
Increased physical activity levels
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular
Obesity
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular
Pain
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular
Alcoholism
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular
Opiate Substitution Treatment
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular
Therapeutic procedure
, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Warnings

Revia Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Withdrawal syndrome
Do Not Combine
Adrenal gland hypofunction
Do Not Combine
There are 20 known major drug interactions with Revia.
Common Revia Drug Interactions
Drug Name
Risk Level
Description
Eluxadoline
Major
The risk or severity of constipation can be increased when Naltrexone is combined with Eluxadoline.
Methylene blue
Major
Naltrexone may increase the serotonergic activities of Methylene blue.
Methylnaltrexone
Major
Naltrexone may increase the opioid antagonism activities of Methylnaltrexone.
Mirtazapine
Major
Naltrexone may increase the serotonergic activities of Mirtazapine.
Naloxegol
Major
Naltrexone may increase the opioid antagonism activities of Naloxegol.
Revia Toxicity & Overdose RiskAnimals have a toxic dose of naltrexone between 1100-1550mg/kg for mice, 1450mg/kg for rats, and 1490mg/kg for guinea pigs. Taking very high doses of naltrexone (generally more than 1000mg/kg) can cause drooling, reduced energy levels, tremors, and seizures.
image of a doctor in a lab doing drug, clinical research

Revia Novel Uses: Which Conditions Have a Clinical Trial Featuring Revia?

Currently, 30 active studies are being conducted to assess the effectiveness of Revia in conjunction with a reduced-calorie diet, Pruritus alleviation and increased physical activity.
Condition
Clinical Trials
Trial Phases
Caloric Restriction
0 Actively Recruiting
Pain
0 Actively Recruiting
Pruritus
0 Actively Recruiting
Comorbidity
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting
Increased physical activity levels
0 Actively Recruiting
Opioid-Related Disorders
0 Actively Recruiting
Opiate Substitution Treatment
0 Actively Recruiting
Obesity
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Alcoholism
7 Actively Recruiting
Not Applicable, Phase 2, Phase 3

Revia Reviews: What are patients saying about Revia?

5Patient Review
2/21/2014
Revia for Prevention of Opiate Drug Abuse
I'm so glad I found this medication! It's been a month and it's working great for me with no side effects. I was using opiates and heroin before, but this pill has been a miracle for me.
5Patient Review
3/23/2009
Revia for Prevention of Opiate Drug Abuse
5Patient Review
1/11/2010
Revia for Prevention of Opiate Drug Abuse
I would like to learn more about this medication.
4.7Patient Review
1/13/2010
Revia for Habit of Drinking Too Much Alcohol
My fiance was an opiate addict for 3 years. He went to rehab and they gave him revia, which caused withdrawal symptoms for the first few days. But he tough it out and now he's been clean for a year! He's made so much progress and is the man I fell in love with again.
4.7Patient Review
5/13/2009
Revia for Prevention of Opiate Drug Abuse
I felt pretty bad after taking this, with diarrhea and still feeling cravings for Lortab.
4.3Patient Review
4/19/2015
Revia for Habit of Drinking Too Much Alcohol
Don't give up on this medication! It really does work, but it may take some time to see results.
4Patient Review
3/20/2011
Revia for Habit of Drinking Too Much Alcohol
I have never tried this treatment before.
3Patient Review
5/13/2011
Revia for Habit of Drinking Too Much Alcohol
I've only taken this medication twice, but I was very nauseous afterwards both times. The second time, I didn't even have dinner because the nausea was so severe. Finally threw up before going to bed. while this pill does seem to be effective as an appetite suppressant, the side effects are not worth it in my opinion.
3Patient Review
8/8/2008
Revia for Habit of Drinking Too Much Alcohol
2.7Patient Review
10/26/2013
Revia for Prevention of Opiate Drug Abuse
I'm not sure what to make of this treatment yet. I only just started taking it last night, so it's too early to tell if it's working or not. They prescribed it to me for cravings, and so far I haven't had any pain medication in 30 days.
1.3Patient Review
8/4/2011
Revia for Prevention of Opiate Drug Abuse
I was given this medication to help with cravings, and I'm now two months clean. However, the side effects were really bad. I constantly felt nauseous, my jaw was clenched all the time, I had headaches and chest pain. Additionally, I lost my appetite and just generally felt sick. I don't think I'll be taking this medication anymore.
1Patient Review
2/22/2016
Revia for Habit of Drinking Too Much Alcohol
I'm about to start this table, but I have an alcohol problem. Are there any other people out there taking it for alcohol?
1Patient Review
8/2/2008
Revia for Prevention of Opiate Drug Abuse
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about revia

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between ReVia and Vivitrol?

"The only form of naltrexone that is FDA-approved for treating opioid use disorder is the injectable form, Vivitrol. Naltrexone in any form will block the effects of opioid drugs. Taking naltrexone reduces your tolerance to opioids."

Answered by AI

What is the meaning of ReVia?

"This drug blocks the action of opiates, which are drugs used to treat pain. It may be used to treat intravenous opiate addiction or alcohol dependence."

Answered by AI

How does naltrexone make you feel?

"Naltrexone works by blocking the parts of the brain that are associated with pleasure from alcohol and drugs. By doing this, it makes it easier to stop drinking."

Answered by AI

How do you use ReVia?

"This medicine is taken by mouth, with or without food. The usual dose is 50 mg per day. You may be monitored by a health care professional when taking this medicine."

Answered by AI

Clinical Trials for Revia

Image of Alpha Neuron LLC in Tuscaloosa, United States.

Deep TMS for Alcoholism

18 - 86
All Sexes
Tuscaloosa, AL
The study will compare alcohol use in two groups of subjects. One group will be assigned to the Deep TMS treatment and the other group will be assigned to the sham treatment. This is a prospective, 6-month, double blind, randomized, controlled, multi-center trial in outpatients recruited in both academic and private research centers. The study population will consist of subjects diagnosed with moderate to severe AUD. The study is comprised of three phases: 1. Pre-study Screening and Baseline Phase 2. Acute Treatment Phase and 3. Maintenance Treatment and Follow up Phase Subjects of all ethnic and gender categories, ages ranging between 18-86 years will be screened for study eligibility according to the inclusion and exclusion criteria. Subjects who meet the eligibility criteria and are willing to sign an informed consent form will be enrolled in the study. The subjects' demographic and baseline characteristics, as well as their overall medical condition will be assessed prior to treatment administration. Eligible patients will be randomized with a 1:1 ratio to one of two study groups (treatment or sham) and stratified by site. Randomization will be employed to avoid bias in the assignment of subjects to treatment group. All subjects will undergo the same treatment regimen, regardless of the assigned treatment group. The acute treatment phase will include 15 treatment visits over a period of 3-5 weeks. The Maintenance Treatment \& Follow-up phase will include one treatment visit per week from the end of the Acute Treatment Phase until the 6 month follow-up visit. At each treatment session, prior to stimulation onset, alcohol related cues will be presented to the subject. After the offset of the alcohol cue presentation, active or sham Deep TMS stimulation will be administered. The study design is directed towards a comparison between active treatment and sham, up to 4 months and 6 months follow-up. Efficacy will be assessed using the primary efficacy measure of the percent heavy drinking days during months 2-4, based on the Time Line Follow Back (TLFB) reporting. Additionally, several subject assessment scales will be used during the course of the study to assess alcohol use and alcohol craving. Safety will be assessed, including monitoring the severity, causality and frequency of all adverse events, vital signs, and physical and neurological examination.
Recruiting
Device
Alpha Neuron LLC (+5 Sites)Brainsway
Image of Wake Forest University Health Sciences in Winston-Salem, United States.

Transcranial Magnetic Stimulation for Alcoholism

21 - 65
All Sexes
Winston-Salem, NC
Alcohol use disorder (AUD) is a complex chronic brain disease characterized by compulsive alcohol use, loss of control over drinking, and negative emotional states. Extensive research has identified the general neural circuitry underlying AUD. There is an exciting opportunity to intervene in AUD using neuromodulation. Transcranial magnetic stimulation (TMS) offers a non-invasive method to modulate brain activity, making it a promising tool for investigating, modulating, and potentially treating AUD. However, the precise effects of TMS on neural circuits involved in AUD and the mechanisms underlying these effects must first be understood. Magnetoencephalography (MEG) is a neuroimaging method that provides direct measurement of brain activity within neural circuits with high temporal resolution. Critically, MEG can measure brain activity in a wide range of frequencies that are consistent with those targeted by TMS. The goal of this proposal is therefore to collect preliminary and feasibility data to support a future NIH grant application that would use MEG to investigate TMS effects in individuals with AUD (iAUD).
Recruiting
Has No Placebo
Wake Forest University Health SciencesMerideth A Addicott, PhD
Image of Washington State University in Spokane, United States.

Virtual Incentive Treatment for Alcoholism

18+
All Sexes
Spokane, WA
The overall objective of this program of research is to utilize phosphatidylethanol (PEth), a blood-based biomarker that can detect alcohol use for up to 28 days to deliver a feasible telehealth-based 26-week CM intervention. This study will test a telehealth PEth-based CM model in a sample of adults with AUD (n=200), recruited via online platforms by randomizing individuals to six months of 1) an online cognitive behavioral therapy for AUD (CBT4CBT) and telehealth PEth-based CM (CM condition) or 2) CBT4CBT and reinforcers for submitting blood samples (no abstinence required) (control condition). Investigators will assess group differences in PEth-defined abstinence and regular excessive drinking (PEth \>= 200 ng/mL), and alcohol-related harms (e.g., smoking, drug use). This study will address important gaps in CM research by assessing outcomes during a 12-month follow-up, which is much longer than most previous CM studies; using a conceptual model to identify predictors of post-treatment abstinence. Investigators will conduct an economic analysis to place the cost of this model in the context of downstream CM-associated cost-offsets and improvements in personal and public health.
Recruiting
Has No Placebo
Washington State UniversityMichael McDonell, PhD
Have you considered Revia clinical trials? We made a collection of clinical trials featuring Revia, we think they might fit your search criteria.Go to Trials
Image of National Institutes of Health Clinical Center, 9000 Rockville Pike in Bethesda, United States.

7T MRI for Studying Addiction

18 - 65
All Sexes
Bethesda, MD
Background: \- Scientists know that alcohol use disorders affect brain structure. They want to know more about the effects of alcohol use disorders on a person s behavior. They want to develop tasks that can be done inside a scanner that can help them better understand these effects in later studies. Objective: \- To develop tasks that investigate a person s behavior that can be used in later studies. Eligibility: * Inpatient participants of another study. They must be physically healthy right-handed adults 18-60 years old. * Healthy right-handed volunteers 18-65 years old. Design: * Participants will be screened with medical history and physical exam. They will have an EKG to record heart activity. They will give blood and urine samples and have a psychiatric interview. * Participants will have between one and three visits. * Participants will be asked about their alcohol drinking to see if they have an alcohol use disorder. * Participants will complete one of three simple computerized tasks either inside the magnetic resonance imagining (MRI) scanner or outside of it. * The MRI scanner takes pictures of the brain. The scanner is a metal cylinder. Participants lie on a table that can slide in and out of the cylinder. They will be in the scanner for about 60 minutes. They may have to lie still for up to 20 minutes. The scanner makes loud knocking noises, but they will get earplugs.
Recruiting
Has No Placebo
National Institutes of Health Clinical Center, 9000 Rockville Pike (+1 Sites)Abdolreza Momenan, Ph.D.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security